Status:

COMPLETED

Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles

Lead Sponsor:

Venus Concept

Conditions:

Acne Scars - Mixed Atrophic and Hypertrophic

Wrinkle

Eligibility:

All Genders

22+ years

Phase:

NA

Brief Summary

The objective of this clinical study is to evaluate the efficacy of fractional RF for the treatment and reduction of acne scarring or facial wrinkles.

Detailed Description

Prospective, single centre, evaluator-blind, split face study of the efficacy of fractional radiofrequency (RF) for the treatment and reduction of acne scarring and facial wrinkles. The study will eva...

Eligibility Criteria

Inclusion

  • Healthy, male or female subjects over 21 years of age who are seeking treatment and reduction of their acne scarring or wrinkles.
  • Able to read, understand and voluntarily provide written Informed Consent.
  • Able and willing to comply with the treatment/follow-up schedule and requirements.
  • Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study and have a negative Urine Pregnancy test at baseline.

Exclusion

  • Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant).
  • Subjects with any implantable metal device in the treatment area
  • Permanent implant in the treated area, such as metal plates and screws (excluding dental implants), or an injected chemical substance.
  • Current or history of any kind of cancer, or dysplastic nevi
  • Severe concurrent conditions, such as cardiac disorders.
  • Pregnancy or intending to become pregnant during the study and nursing.
  • Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications.
  • History of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; may be enrolled only following a prophylactic regime.
  • Poorly controlled endocrine disorders, such as diabetes.
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
  • History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin.
  • History of bleeding coagulopathies, or use of anticoagulants (excluding daily aspirin).
  • Facial dermabrasion, facial resurfacing, or deep chemical peeling within the last three months, if face is treated.
  • Use of isotretinoin (Accutane®) or other systemic retinoids within six months prior to treatment or as per investigators discretion.
  • Any surgical procedure in the treatment area within the last six months or before complete healing.
  • Treating over tattoo or permanent makeup.
  • Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.

Key Trial Info

Start Date :

August 19 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 3 2020

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT04057768

Start Date

August 19 2019

End Date

March 3 2020

Last Update

June 29 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Laser and Skin Surgery Center of Northern California

Sacramento, California, United States, 95816